Coagulation Factors - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509240513

Publication Date:

September 24, 2024

Pages:

124

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Coagulation factors听such as factor V, factor VIII and factor X play a role in blood clotting
The global market for Coagulation Factors was estimated to be worth US$ 12770 million in 2023 and is forecast to a readjusted size of US$ 18800 million by 2030 with a CAGR of 5.8% during the forecast period 2024-2030
The coagulation factors market has experienced substantial growth in recent years. Coagulation factors are essential proteins involved in the blood clotting process, and deficiencies or abnormalities in these factors can lead to bleeding disorders such as hemophilia and von Willebrand disease. The market growth can be attributed to several factors. Firstly, the increasing prevalence of bleeding disorders, driven by factors such as genetic predisposition, aging population, and improved diagnostic capabilities, has fueled the demand for coagulation factor products. Additionally, advancements in recombinant DNA technology and biotechnology have enabled the development of highly purified and more effective coagulation factor concentrates, offering improved treatment options for patients.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Coagulation Factors, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Coagulation Factors by region & country, by Type, and by Application.
The Coagulation Factors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Coagulation Factors.
麻豆原创 Segmentation
By Company
Takeda
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Segment by Type:
Plasma-derived
Recombinant
Segment by Application
Pharmacy
Hospital
By Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Coagulation Factors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Coagulation Factors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Coagulation Factors in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Coagulation Factors Product Introduction
1.2 Global Coagulation Factors 麻豆原创 Size Forecast
1.2.1 Global Coagulation Factors Sales Value (2019-2030)
1.2.2 Global Coagulation Factors Sales Volume (2019-2030)
1.2.3 Global Coagulation Factors Sales Price (2019-2030)
1.3 Coagulation Factors 麻豆原创 Trends & Drivers
1.3.1 Coagulation Factors Industry Trends
1.3.2 Coagulation Factors 麻豆原创 Drivers & Opportunity
1.3.3 Coagulation Factors 麻豆原创 Challenges
1.3.4 Coagulation Factors 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Coagulation Factors Players Revenue Ranking (2023)
2.2 Global Coagulation Factors Revenue by Company (2019-2024)
2.3 Global Coagulation Factors Players Sales Volume Ranking (2023)
2.4 Global Coagulation Factors Sales Volume by Company Players (2019-2024)
2.5 Global Coagulation Factors Average Price by Company (2019-2024)
2.6 Key Manufacturers Coagulation Factors Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Coagulation Factors Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Coagulation Factors
2.9 Coagulation Factors 麻豆原创 Competitive Analysis
2.9.1 Coagulation Factors 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Coagulation Factors Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Coagulation Factors as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Plasma-derived
3.1.2 Recombinant
3.2 Global Coagulation Factors Sales Value by Type
3.2.1 Global Coagulation Factors Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Coagulation Factors Sales Value, by Type (2019-2030)
3.2.3 Global Coagulation Factors Sales Value, by Type (%) (2019-2030)
3.3 Global Coagulation Factors Sales Volume by Type
3.3.1 Global Coagulation Factors Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Coagulation Factors Sales Volume, by Type (2019-2030)
3.3.3 Global Coagulation Factors Sales Volume, by Type (%) (2019-2030)
3.4 Global Coagulation Factors Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pharmacy
4.1.2 Hospital
4.2 Global Coagulation Factors Sales Value by Application
4.2.1 Global Coagulation Factors Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Coagulation Factors Sales Value, by Application (2019-2030)
4.2.3 Global Coagulation Factors Sales Value, by Application (%) (2019-2030)
4.3 Global Coagulation Factors Sales Volume by Application
4.3.1 Global Coagulation Factors Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Coagulation Factors Sales Volume, by Application (2019-2030)
4.3.3 Global Coagulation Factors Sales Volume, by Application (%) (2019-2030)
4.4 Global Coagulation Factors Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Coagulation Factors Sales Value by Region
5.1.1 Global Coagulation Factors Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Coagulation Factors Sales Value by Region (2019-2024)
5.1.3 Global Coagulation Factors Sales Value by Region (2025-2030)
5.1.4 Global Coagulation Factors Sales Value by Region (%), (2019-2030)
5.2 Global Coagulation Factors Sales Volume by Region
5.2.1 Global Coagulation Factors Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Coagulation Factors Sales Volume by Region (2019-2024)
5.2.3 Global Coagulation Factors Sales Volume by Region (2025-2030)
5.2.4 Global Coagulation Factors Sales Volume by Region (%), (2019-2030)
5.3 Global Coagulation Factors Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Coagulation Factors Sales Value, 2019-2030
5.4.2 North America Coagulation Factors Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Coagulation Factors Sales Value, 2019-2030
5.5.2 Europe Coagulation Factors Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Coagulation Factors Sales Value, 2019-2030
5.6.2 Asia Pacific Coagulation Factors Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Coagulation Factors Sales Value, 2019-2030
5.7.2 South America Coagulation Factors Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Coagulation Factors Sales Value, 2019-2030
5.8.2 Middle East & Africa Coagulation Factors Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Coagulation Factors Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Coagulation Factors Sales Value
6.2.1 Key Countries/Regions Coagulation Factors Sales Value, 2019-2030
6.2.2 Key Countries/Regions Coagulation Factors Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Coagulation Factors Sales Value, 2019-2030
6.3.2 United States Coagulation Factors Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Coagulation Factors Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Coagulation Factors Sales Value, 2019-2030
6.4.2 Europe Coagulation Factors Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Coagulation Factors Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Coagulation Factors Sales Value, 2019-2030
6.5.2 China Coagulation Factors Sales Value by Type (%), 2023 VS 2030
6.5.3 China Coagulation Factors Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Coagulation Factors Sales Value, 2019-2030
6.6.2 Japan Coagulation Factors Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Coagulation Factors Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Coagulation Factors Sales Value, 2019-2030
6.7.2 South Korea Coagulation Factors Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Coagulation Factors Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Coagulation Factors Sales Value, 2019-2030
6.8.2 Southeast Asia Coagulation Factors Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Coagulation Factors Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Coagulation Factors Sales Value, 2019-2030
6.9.2 India Coagulation Factors Sales Value by Type (%), 2023 VS 2030
6.9.3 India Coagulation Factors Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Takeda
7.1.1 Takeda Company Information
7.1.2 Takeda Introduction and Business Overview
7.1.3 Takeda Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Takeda Coagulation Factors Product Offerings
7.1.5 Takeda Recent Development
7.2 Bayer
7.2.1 Bayer Company Information
7.2.2 Bayer Introduction and Business Overview
7.2.3 Bayer Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Bayer Coagulation Factors Product Offerings
7.2.5 Bayer Recent Development
7.3 CSL
7.3.1 CSL Company Information
7.3.2 CSL Introduction and Business Overview
7.3.3 CSL Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
7.3.4 CSL Coagulation Factors Product Offerings
7.3.5 CSL Recent Development
7.4 Pfizer
7.4.1 Pfizer Company Information
7.4.2 Pfizer Introduction and Business Overview
7.4.3 Pfizer Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Pfizer Coagulation Factors Product Offerings
7.4.5 Pfizer Recent Development
7.5 Grifols
7.5.1 Grifols Company Information
7.5.2 Grifols Introduction and Business Overview
7.5.3 Grifols Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Grifols Coagulation Factors Product Offerings
7.5.5 Grifols Recent Development
7.6 Biogen
7.6.1 Biogen Company Information
7.6.2 Biogen Introduction and Business Overview
7.6.3 Biogen Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Biogen Coagulation Factors Product Offerings
7.6.5 Biogen Recent Development
7.7 Octapharma
7.7.1 Octapharma Company Information
7.7.2 Octapharma Introduction and Business Overview
7.7.3 Octapharma Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Octapharma Coagulation Factors Product Offerings
7.7.5 Octapharma Recent Development
7.8 NovoNordisk
7.8.1 NovoNordisk Company Information
7.8.2 NovoNordisk Introduction and Business Overview
7.8.3 NovoNordisk Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
7.8.4 NovoNordisk Coagulation Factors Product Offerings
7.8.5 NovoNordisk Recent Development
7.9 Greencross
7.9.1 Greencross Company Information
7.9.2 Greencross Introduction and Business Overview
7.9.3 Greencross Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Greencross Coagulation Factors Product Offerings
7.9.5 Greencross Recent Development
7.10 Kedrion
7.10.1 Kedrion Company Information
7.10.2 Kedrion Introduction and Business Overview
7.10.3 Kedrion Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Kedrion Coagulation Factors Product Offerings
7.10.5 Kedrion Recent Development
7.11 BPL
7.11.1 BPL Company Information
7.11.2 BPL Introduction and Business Overview
7.11.3 BPL Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
7.11.4 BPL Coagulation Factors Product Offerings
7.11.5 BPL Recent Development
7.12 Hualan Bio
7.12.1 Hualan Bio Company Information
7.12.2 Hualan Bio Introduction and Business Overview
7.12.3 Hualan Bio Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Hualan Bio Coagulation Factors Product Offerings
7.12.5 Hualan Bio Recent Development
7.13 RAAS
7.13.1 RAAS Company Information
7.13.2 RAAS Introduction and Business Overview
7.13.3 RAAS Coagulation Factors Sales, Revenue and Gross Margin (2019-2024)
7.13.4 RAAS Coagulation Factors Product Offerings
7.13.5 RAAS Recent Development
8 Industry Chain Analysis
8.1 Coagulation Factors Industrial Chain
8.2 Coagulation Factors Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Coagulation Factors Sales Model
8.5.2 Sales Channel
8.5.3 Coagulation Factors Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Takeda
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.